Norbrook Laboratories Ltd. announced the addition of a new 500 mL bottle of its Food & Drug Administration-approved Enroflox 100 (enrofloxacin) for the single day, single-dose treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle.
Containing the same active ingredient and dosing regimen as Baytril 100 (enrofloxacin) in beef and non-lactating dairy cattle, Enroflox 100, is also approved for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
In swine, Enroflox 100 is approved for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.
“Veterinarians and producers have been asking for a 500 mL bottle of Enroflox 100 to compliment the 100 mL and 250 mL bottles launched in 2013,” said Norbrook food animal marketing manager Chip Whitlow. “The new 500 mL bottle is available immediately and provides a more efficient size when treating large numbers of head.”